Guide
Microdose Semaglutide 2026: Cost, and What the Evidence Does Not Say
Microdose programmes use doses below the approved starting dose. The cheapest we captured is $110 a month on a twelve-month plan, $1,320 a year — about $420 less than ful
Microdose programmes use doses below the approved starting dose. The cheapest we captured is $110 a month on a twelve-month plan, $1,320 a year — about $420 less than full dose. The evidence position matters more than the price: microdoses sit below every dose studied in STEP-1, so no published efficacy figure applies to them at any price.
What is microdosing, in plain terms?
Approved labelling for chronic weight management describes a schedule beginning at 0.25 mg weekly and stepping up to a 2.4 mg maintenance dose. A microdose programme uses amounts below that starting dose.
People choose it for tolerability, because gastrointestinal effects cluster at each dose increase, and for maintenance after reaching a goal. Both are plausible. Neither has been tested in a trial of this molecule at these doses.
STEP-1 studied 2.4 mg. SELECT studied 2.4 mg. A microdose is below the lowest dose in either.
So the 14.9% weight-loss figure and the 20% cardiovascular risk reduction do not describe what a microdose programme delivers. Anyone quoting those numbers beside a microdose price is quoting evidence that was not collected on the product being sold.
We say this on the page that also carries the prices, because a reader deciding on cost deserves the evidence position in the same place.
What does it cost against a full dose?
| Term | Microdose | Full dose | Difference |
|---|---|---|---|
| Month-to-month | $129 | $165 | −$36 |
| 3-month | $117 | $149 | −$32 |
| 6-month | $114 | $147 | −$33 |
| 12-month | $110 | $145 | −$35 |
| Twelve-month total | $1,320 | $1,740 | −$420 |
About $420 a year separates them. That is a real saving, and it buys a product whose dose sits outside the trial evidence.
Why is the cheapest row not automatically the best buy?
Ranked on price alone a microdose programme wins every table it appears in. That is precisely why we keep the protocols separate: a microdose figure and a full-dose figure are not comparable, and a comparison site that sorts them together produces a ranking that is arithmetically correct and practically misleading.
What should I ask before starting?
- What dose, in milligrams? “Microdose” is a marketing word, not a defined quantity.
- What is the clinical rationale for me specifically? Since 2025 the surviving compounding route requires a prescriber to document a clinical difference for the individual patient.
- Does the price change if I move to a full dose? On the programme we captured it does.
- What evidence are you relying on? If the answer quotes STEP-1, it is quoting a dose the programme does not supply.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What is the salt-form question?
Semaglutide sodium and semaglutide acetate are not the same active ingredient as the base form in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. Ask for the exact salt form and concentration in writing. Tirzepatide has no equivalent question.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| NexLife | Yes | Yes | Yes | Yes | Yes | Yes | 6 of 6 |
| Mochi Health | Yes | Yes | Yes | — | — | Yes | 4 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.
These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Does microdosing semaglutide work?
No published trial has tested semaglutide at microdoses for weight management. STEP-1 and SELECT both studied 2.4 mg, above the range microdose programmes use.
How much does microdose semaglutide cost?
The cheapest we captured is $110 a month on a twelve-month plan, $1,320 a year — about $420 less than the same provider's full-dose programme.
What counts as a microdose?
There is no defined quantity. It is a marketing term for amounts below the approved 0.25 mg starting dose. Ask any provider for the figure in milligrams.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Microdose vs Standard-Dose TirzepatideComparisons
- Microdose Tirzepatide: Evidence, Cost and LimitationsPillar / Money
- Microdose Tirzepatide: The Evidence GapJournal
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
- GLP-1 Tirzepatide Ranked: Evidence, Prices, Providers & ToolsCore & Trust
- How Dose Escalation Changes Tirzepatide CostJournal
Related coverage
GLP-1 Tirzepatide Ranked. “Microdose Semaglutide 2026: Cost, and What the Evidence Does Not Say.” S.J Partners LLC, 2026-07-26. https://glp1tirzepatideranked.com/microdose-semaglutide-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.